Anterogencoltd Stock Fundamentals
| 065660 Stock | KRW 19,740 1,420 7.75% |
AnterogenCoLtd fundamentals help investors to digest information that contributes to AnterogenCoLtd's financial success or failures. It also enables traders to predict the movement of AnterogenCoLtd Stock. The fundamental analysis module provides a way to measure AnterogenCoLtd's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AnterogenCoLtd stock.
AnterogenCoLtd |
AnterogenCoLtd Company Current Valuation Analysis
AnterogenCoLtd's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AnterogenCoLtd Current Valuation | 836.51 B |
Most of AnterogenCoLtd's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AnterogenCoLtd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AnterogenCoLtd has a Current Valuation of 836.51 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The current valuation for all Republic of Korea stocks is significantly lower than that of the firm.
AnterogenCoLtd Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining AnterogenCoLtd's current stock value. Our valuation model uses many indicators to compare AnterogenCoLtd value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AnterogenCoLtd competition to find correlations between indicators driving AnterogenCoLtd's intrinsic value. More Info.AnterogenCoLtd is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value AnterogenCoLtd by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AnterogenCoLtd's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. AnterogenCoLtd is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Pharmaceuticals industry is presently estimated at about 876.66 Billion. AnterogenCoLtd totals roughly 836.51 Billion in current valuation claiming about 95% of equities listed under Pharmaceuticals industry.AnterogenCoLtd Fundamentals
| Return On Equity | -5.92 | |||
| Return On Asset | -0.0231 | |||
| Profit Margin | (1.32) % | |||
| Operating Margin | (0.77) % | |||
| Current Valuation | 836.51 B | |||
| Shares Outstanding | 7.95 M | |||
| Shares Owned By Insiders | 21.02 % | |||
| Shares Owned By Institutions | 5.63 % | |||
| Price To Sales | 103.53 X | |||
| Revenue | 8.12 B | |||
| Gross Profit | 1.72 B | |||
| EBITDA | (2.96 B) | |||
| Net Income | (553.98 M) | |||
| Cash And Equivalents | 6.97 B | |||
| Debt To Equity | 43.70 % | |||
| Current Ratio | 3.83 X | |||
| Cash Flow From Operations | (3.05 B) | |||
| Beta | 0.37 | |||
| Market Capitalization | 108.41 B | |||
| Total Asset | 136.7 B | |||
| Net Asset | 136.7 B |
About AnterogenCoLtd Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AnterogenCoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AnterogenCoLtd using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AnterogenCoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea. ANTEROGEN is traded on Korean Securities Dealers Automated Quotations in South Korea.
Other Information on Investing in AnterogenCoLtd Stock
AnterogenCoLtd financial ratios help investors to determine whether AnterogenCoLtd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AnterogenCoLtd with respect to the benefits of owning AnterogenCoLtd security.